| Chronic Obstructive Airway Disease
Stiolto Respimat vs Dalisrep
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Stiolto Respimat vs Daliresp with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDaliresp has a higher rate of injection site reactions vs Stiolto Respimat based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Daliresp but not Stiolto Respimat, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stiolto Respimat
Daliresp
At A Glance
Oral inhalation
Once daily
LAMA/LABA
Oral
Daily
PDE4 inhibitor
Indications
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Chronic Obstructive Airway Disease Maintenance dose: 500 mcg once daily, with or without food; an optional titration of 250 mcg once daily for the first 4 weeks may reduce discontinuation rates, but 250 mcg is not the effective therapeutic dose.
Contraindications
- Use of LABA without inhaled corticosteroid in patients with asthma
- Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Most common (>=2%) Diarrhea, weight decreased, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite
Serious Diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure
Postmarketing Hypersensitivity reactions (angioedema, urticaria, rash), gynecomastia
Pharmacology
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4); inhibition of PDE4 leads to accumulation of intracellular cyclic AMP in lung tissue, which is thought to underlie its therapeutic action in COPD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stiolto Respimat
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Daliresp
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Stiolto Respimat
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Daliresp
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Stiolto Respimat
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Daliresp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Stiolto Respimat.
No savings programs available for Daliresp.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Stiolto RespimatView full Stiolto Respimat profile
DalirespView full Daliresp profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.